Leivonen S-K, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen V N, Børresen-Dale A-L, Saviranta P, Perälä M, Kallioniemi O
Medical Biotechnology, VTT Technical Research Centre of Finland, and Centre for Biotechnology, University of Turku, Turku, Finland.
Oncogene. 2009 Nov 5;28(44):3926-36. doi: 10.1038/onc.2009.241. Epub 2009 Aug 17.
Predicting the impact of microRNAs (miRNAs) on target proteins is challenging because of their different regulatory effects at the transcriptional and translational levels. In this study, we applied a novel protein lysate microarray (LMA) technology to systematically monitor for target protein levels after high-throughput transfections of 319 pre-miRs into breast cancer cells. We identified 21 miRNAs that downregulated the estrogen receptor-alpha (ERalpha), as validated by western blotting and quantitative real time-PCR, and by demonstrating the inhibition of estrogen-stimulated cell growth. Five potent ERalpha-regulating miRNAs, miR-18a, miR-18b, miR-193b, miR-206 and miR-302c, were confirmed to directly target ERalpha in 3'-untranslated region reporter assays. The gene expression signature that they repressed highly overlapped with that of a small interfering RNA against ERalpha, and across all the signatures tested, was most closely associated with the repression of known estrogen-induced genes. Furthermore, miR-18a and miR-18b showed higher levels of expression in ERalpha-negative as compared with ERalpha-positive clinical tumors. In summary, we present systematic and direct functional evidence of miRNAs inhibiting ERalpha signaling in breast cancer, and demonstrate the high-throughput LMA technology as a novel, powerful technique in determining the relative impact of various miRNAs on key target proteins and associated cellular processes and pathways.
预测微小RNA(miRNA)对靶蛋白的影响具有挑战性,因为它们在转录和翻译水平上具有不同的调控作用。在本研究中,我们应用了一种新型的蛋白质裂解物微阵列(LMA)技术,在将319种前体miR高通量转染到乳腺癌细胞后,系统地监测靶蛋白水平。我们鉴定出21种下调雌激素受体α(ERα)的miRNA,通过蛋白质印迹法和定量实时PCR进行验证,并通过证明其对雌激素刺激的细胞生长的抑制作用来证实。在3'-非翻译区报告基因分析中,5种有效的ERα调节miRNA,即miR-18a、miR-18b、miR-193b、miR-206和miR-302c,被证实直接靶向ERα。它们所抑制的基因表达特征与针对ERα的小干扰RNA的特征高度重叠,并且在所有测试的特征中,与已知雌激素诱导基因的抑制最为密切相关。此外,与ERα阳性临床肿瘤相比,miR-18a和miR-18b在ERα阴性肿瘤中表达水平更高。总之,我们提供了miRNA在乳腺癌中抑制ERα信号传导的系统和直接功能证据,并证明了高通量LMA技术是一种新型、强大的技术,可用于确定各种miRNA对关键靶蛋白以及相关细胞过程和途径的相对影响。